PAK1 and breast carcinoma: This study used both pharmacological and molecular approaches to investigate the hypothesis that the efficacy of free IPA‐3 and SSL‐IPA‐3 is dependent on the expression of PAK‐1 in diverse cancer cells, including prostate and breast cancer, as well as melanoma cells.